Leidos Holdings, Inc. (NYSE:LDOS – Free Report) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Leidos in a research note issued on Tuesday ...
Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for CACI International’s current full-year earnings is $23.94 per share. Get CACI International alerts: ...
Hosted on MSN16d
Cantor Fitzgerald Downgrades Jazz Pharmaceuticals (JAZZ)Fintel reports that on February 26, 2025, Cantor Fitzgerald downgraded their outlook for Jazz Pharmaceuticals (NasdaqGS:JAZZ) from Overweight to Neutral. Analyst Price Forecast Suggests 30.34% ...
The Central Bank has fined the Irish unit of US investment group Cantor Fitzgerald €452,790 for failing to report suspicious transactions that may have indicated market abuse. Between March 2017 ...
The Central Bank said Cantor failed on a number of occasions to report identified suspicious transactions that may have indicated market abuse. The Central Bank of Ireland fined Cantor Fitzgerald ...
In a report released today, Andres Sheppard from Cantor Fitzgerald maintained a Buy rating on Joby Aviation (JOBY – Research Report), with a price target of $9.00. The company’s shares closed ...
On Wednesday, Cantor Fitzgerald reaffirmed its confidence in Harmony Biosciences Holdings Inc. (NASDAQ:HRMY), maintaining an Overweight rating with a steady price target of $54.00. The firm’s ...
will participate in a fireside chat at Cantor Fitzgerald Global Technology Conference on Tuesday, March 11, 2025 at 1:00 p.m. EDT. A live webcast of the session will be available in the Investor ...
Cantor Fitzgerald sees a significant event for NVIDIAthe expected Blackwell product release in the July quarter. Analysts think Blackwell might be a significant trigger, maybe influencing market ...
Cantor Fitzgerald sees a significant event for NVIDIAthe expected Blackwell product release in the July quarter. Analysts think Blackwell might be a significant trigger, maybe influencing market mood ...
Fintel reports that on February 26, 2025, Cantor Fitzgerald downgraded their outlook for Jazz Pharmaceuticals (BRSE:J7Z) from Overweight to Neutral. There are 1,021 funds or institutions reporting ...
will participate in a fireside chat at Cantor Fitzgerald Global Technology Conference on Tuesday, March 11, 2025 at 1:00 p.m. EDT. A live webcast of the session will be available in the Investor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results